Sustained CD4 and CD8 lymphopenia after rituximab maintenance therapy following bendamustine and rituximab combination therapy for lymphoma

Leukemia and Lymphoma

Volumn 56, Issue 11, 2015, Pages 3216-3218

  Yutaka, Tsutsumi ^a   Ito, Shinichi ^a   Ohigashi, Hiroyuki ^a   Naohiro, Miyashita ^a   Shimono, Joji ^a   Souichi, Shiratori ^a   Teshima, Takanori ^b  

^a Hakodate Municipal Hospital   (Japan)

^b HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BENDAMUSTINE; CD4 ANTIGEN; CD8 ANTIGEN; RITUXIMAB; ANTINEOPLASTIC AGENT;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CD4 LYMPHOCYTE COUNT; CELL COUNT; DISEASE COURSE; FOURNIER GANGRENE; HERPES ZOSTER; HUMAN; INFECTION COMPLICATION; LYMPHOCYTOPENIA; LYMPHOMA; MAINTENANCE THERAPY; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RISK ASSESSMENT; SEPSIS; TREATMENT RESPONSE; BLOOD; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; COMPLICATION; LYMPHOCYTE COUNT; LYMPHOPENIA; MAINTENANCE CHEMOTHERAPY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENDAMUSTINE HYDROCHLORIDE; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; HUMANS; LYMPHOCYTE COUNT; LYMPHOMA; LYMPHOPENIA; MAINTENANCE CHEMOTHERAPY; RITUXIMAB;

EID: 84947754736     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2015.1026818     Document Type: Article

References (10)

1. Finn IW, van der Jagt R, Kahl BS, et al. Randomized trial of bendamustine-rituximab or R-CHOP/CVP in first line treatment of indolent NHL or MCL: the Bright study. Blood 2014; 123: 2944-2952.
2. Misumi I, Whitmire JK. B cell depression crutalis CD4 + T cell memory and reduces protection against disseminating virus infection. J Immunol 2014; 192; 1597-1608.
3. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25: 579-586.
4. Layman RM, Ruppert AS, Lynn M, et al. Severe and prolonged lymphopenia observed in patients treated with bendamustine and erlotinib for metastatic triple negative breast cancer. Cancer Chemotherapy Pharmacol 2013; 71: 1183-1190.
5. Ohmachi K, Niitsu N, Uchida T, et al. Multicenter phase II study of bendamustine pus rituximab in patients with relapse or refractory diffuse large B cell lymphoma. J Clin Oncol 2013; 31: 2103-2010.
6. Besada E, Koldingsnes W, Nossent C. Long-term efficacy and safety of pre-emptive maintenance therapy with rituximab in granulomatosis with polyangitis: results from a single center. Rheumatology 2013; 52: 2041-2047.
7. Melet J, Mulleman D, Goupille P, et al. Rituximab-induced T cell depletion in patients with rheumatoid arthritis: association with clinical response. Arthritis Rheum 2013; 65: 2783-2790.
8. Cheson BD, Wendtner CM, Pieper A, et al. Optimal use of bendamustine in chronic lymphocytic leukemia, non-Hodgkin's lymphomas, and multiple myeloma: treatment recommendations from an international consensus panel. Clin Lymphoma Myeloma Leuk 2010; 10: 21-27.
9. Lim SH, Pathapati S, Langevin J, et al. Severe CMV reactivation and gastritis during treatment of follicular lymphoma with bendamustine. Ann Hematol 2012; 91: 643.
10. Carter SJ, Bernstein SH, Friedberg JW, et al. Pneumocystis jirovecii pneumonia as a complication of bendamustine in a patient receiving bendamustine plus rituximab for marginal zone lymphoma. Leuk Res 2011; 35: e233-e234.